Multiple Myeloma Support + Trials

What's the purpose of this trial?

The goal of this clinical trial is to determine the safest and most effective dose of Modakafusp Alfa when given by itself and when combined with Dexamethasone to patients who have relapsed / refractory Multiple Myeloma.

This trial is currently open and accepting patients.

What will happen during the trial?

This trial is being conducted in three different parts, and Part 3 is currently enrolling. The goal of this part of the trial is to learn if two different doses of Modakafusp Alfa are safe and how well they work in treating relapsed or refractory multiple myeloma. This part of the trial will enroll approximately 236 patients.

Participants in this part of the trial will receive treatment organized into 28-day cycles and will receive Modakafusp Alfa by intravenous infusion monthly at one of two different doses. This trial is open label, which means that both the participants and health care providers will know which dose they are receiving.

Participants in this trial may continue to participate as long as they don’t develop bad side effects, and their myeloma doesn’t get worse.

Reasonable travel costs (including transportation, mileage and/or parking relating to you attending the study clinic) may be reimbursed. Additionally, lodging and meal costs may be reimbursed if the study protocol requires extended visits or certain procedures. You may be reimbursed for these costs by your study doctor or his or her staff or through a third-party vendor.

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Participants must have previously received at least three lines of therapy, including an immunomodulatory agent, proteasome inhibitor, alkylating agent and/or anti-CD38 antibody.
Participants must either be refractory or intolerant to at least one immunomodulatory agent and one anti-CD38 antibody.
Participants must not have IgM subtype myeloma.
Participants must have not received an autologous stem cell transplant in the last 60 days and have not had an allogeneic stem cell transplant in the last 6 months.
Participants must have adequate bone marrow, kidney, liver and cardiac function as described in the clinical protocol.
Participants must not have central nervous system involvement of their myeloma.

Additional Trial Information

Phase 1/2

Enrollment: 336 patients (estimated)

Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

June 11, 2022

As of Oct 2021, 30 pts had received modakafusp alfa 1.5 mg/kg Q4W. The median number of prior lines was 7 (range 3–16); 90% of pts were refractory to an anti-CD38 monoclonal antibody (mAb), while 37% were exposed to an anti-B-cell maturation agent (BCMA). Grade (G) 3–4 treatment-emergent adverse events (TEAEs) were reported in 25 pts (83%); the most frequent G3–4 TEAEs were neutropenia in 19 (63%), thrombocytopenia in 13 (43%), leukopenia in 12 (40%), anemia in 9 (30%), and decreased lymphocyte count in 9 (30%) pts. As reported previously, 1 pt in the 1.5 mg/kg Q4W cohort had a G3 bleeding event, while 3 pts had G3 infections. Among all pts, the ORR was 40% (complete response, 7%; very good partial response, 20%; partial response, 13%); among anti-CD38 mAb-refractory and anti BMCA-exposed pts, the ORR was 37% and 27%, respectively. Median progression-free survival was 6 mos and median duration of response had not been reached (Kaplan-Meier estimate, 91% at 6 mos). Based on pooled available data for the Q3W and Q4W cohorts (all doses) within the escalation and expansion phases, there was a strong trend for a dose-exposure-response relationship for ORR, with the apparent inflection point at 1.5 mg/kg Q4W dosing. No apparent relationship between dose-exposure-response and G3/4 thrombocytopenia or neutropenia was observed across all doses, whereas a correlation between dose-exposure-response and incidence of infusion-related reactions across the 0.4–6 mg/kg Q3W and Q4W dosing cohorts was found. There was an apparent non-linear (more than dose proportional) increase in exposure in the dose range of 0.1–3 mg/kg with a geometric mean terminal half-life of 13 hours in serum for modakafusp alfa 1.5 mg/kg. Based on the available data, 14% and 60% of pts were ADA positive at baseline and post-treatment, respectively.

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

December 13, 2021

As of May 2021, 83 pts had been treated across all planned dosing schedules. With Q4W dosing, the MTD was exceeded at the 6 mg/kg dose due to DLTs: a grade 3 infusion reaction and prolonged thrombocytopenia and neutropenia, which delayed the start of cycle 2 by >14 days. In total, 24 pts were treated with 1.5 mg/kg modakafusp alfa Q4W (5 pts during dose escalation and 19 pts in an expansion cohort). Analyses include data from all 24 pts. The median number of prior lines of therapy received was 6 (range 4–16); 21 pts (88%) were refractory to an anti-CD38 mAb, and 20 (83%) were triple class-refractory (to a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 mAb). Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported in 18 pts (75%). The most frequent grade 3–4 TEAEs were neutropenia in 12 pts (50%; grade 4 in 6 [25%]), leukopenia in 9 (38%), decreased lymphocyte count in 9 (38%), anemia in 8 (33%), and thrombocytopenia in 8 (33%; grade 4 in 3 [13%]). One pt (4%) had a grade 3 bleeding event and continues on study treatment; 3 pts (13%) had infections (grade 3 in 2 [8%]); and 8 (33%) had infusion reactions (grade 3 in 1 [4%]). The overall response rate (ORR, ≥partial response [PR]) was 42% (complete response [CR], n=2; very good partial response [VGPR], n=5; PR, n=3), and the clinical benefit rate (ORR + minimal response [MR]) was 54% (MR, n=3). Median progression-free survival was 5.7 months (95% confidence interval [CI], 1.9–not reached [NR]), median time to response was 1.9 months (95% CI, 0.95–NR), and median duration of response was 7.4 months (95% CI, 2.3–NR). Among the 21 anti-CD38 mAb-refractory pts, the ORR was 43%, while among the 4 pts who received an anti-CD38 mAb in their most recent line of therapy prior to enrollment, the ORR was 75% (CR, n=1; VGPR, n=2). Correlative studies show evidence of T-cell and natural killer-cell activation, as well as activation of IFN signaling in CD38+ cells, including upregulation of CD38 expression.

Interested in this trial?

Call us today 😀

We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206

Add this trial to your favorites

If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

Find a nearby location

You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby Locations

Talk to your doctor

You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

What's the purpose of this trial?

What will happen during the trial?

You may be able to join this trial if you:

Additional Trial Information

Published Results

MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

Trial Locations

All Trial Locations

Arkansas

Open and Accepting

California

Open and Accepting

Not Yet Accepting

Open and Accepting

Connecticut

Open and Accepting

Georgia

Open and Accepting

Illinois

Not Yet Accepting

Not Yet Accepting

Indiana

Not Yet Accepting

Maryland

Open and Accepting

Massachusetts

Open and Accepting

Open and Accepting

Nebraska

Open and Accepting

Nevada

Open and Accepting

New Jersey

Open and Accepting

New York

Open and Accepting

Not Yet Accepting

Not Yet Accepting

North Carolina

Not Yet Accepting

Open and Accepting

Open and Accepting

Ohio

Open and Accepting

Open and Accepting

Oregon

Not Yet Accepting

Pennsylvania

Not Yet Accepting

Open and Accepting

Not Yet Accepting

Tennessee

Not Yet Accepting